Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Frederik Persson MD, DMSc

Frederik Persson MD, DMSc

Senior Researcher, Steno Diabetes Center, Copenhagen, Denmark.

Frederik Persson, MD, DMSc is an endocrinologist and senior researcher at Steno Diabetes Center Copenhagen, Denmark, in a research group headed by Professor Peter Rossing. The group has a long-standing interest in the epidemiology, pathophysiology, prevention and treatment of diabetic complications Dr. Persson has been involved in clinical studies of the renin-angiotensin-aldosterone system with special focus on renin inhibition. Additional focus is on renal and cardiovascular effects of GLP-1 RA as well SGLT2i, both in randomized trials and in a real-world setting. Current projects include investigation of new pathways to predict and prevent diabetic nephropathy.

Disclosures

Dr. Persson reports the following:
  • Research grants from AstraZeneca, Novo Nordisk and Novartis
  • Lecture fees from Novartis, Eli Lilly, MSD, AstraZeneca, Sanofi, Novo Nordisk and Boehringer Ingelheim
  • Consultant for Astra Zeneca, Bayer, Amgen, Novo Nordisk and MSD

Recent Contributions to PracticeUpdate:

  1. Association Between SGLT2 Inhibitor Use and a Reduced Risk for New-Onset Type 2 Diabetes in Adults With Prediabetes

Most Read This Week

Recently Updated